Article

Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination

2022-03-18

Abstract excerpt

<h4>Background</h4> The Sinovac SARS-CoV-2 inactivated vaccine (CoronaVac) has been demonstrated to be safe, well tolerated, and efficacious in preventing mild and severe Covid-19. Although different studies have demonstrated its short-term immunogenicity, long-term cellular and humoral response evaluations are still lacking. <h4>Methods</h4> Cellular and humoral responses were assessed after enrollment of volunte...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bf03ec5e-4787-538b-92d5-86c751acddbe
DOI: 10.1101/2022.03.16.22272513

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccinationDOI 10.1101/2022.03.16.22272513Read

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity Read

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upSemantic proximity Read

Immunity to SARS-CoV-2 up to 15 months after infectionSemantic proximity Read

Longitudinal analyses after COVID-19 recovery or prolonged infection reveal unique immunological signatures after repeated vaccinationsSemantic proximity Read

Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patientsSemantic proximity Read

Cellular immune response to SARS-CoV-2 infection in humans: a systematic reviewSemantic proximity Read

A review of leading COVID-19 vaccines, the quest for immune protection, and its key challenges. Part 3: Covid-19 vaccines – Key challenges and translational scienceSemantic proximity Read

The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variantsSemantic proximity Read

Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trialSemantic proximity Read

Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case seriesSemantic proximity Read

T Cell Responses to SARS-CoV-2Semantic proximity Read

Real-world monitoring of BNT162b2 vaccine-induced SARS-CoV-2 B and T cell immunity in naive healthcare workers: a prospective single center studySemantic proximity Read